Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study

Suporn Chuncharunee, Raymond Wong, Ponlapat Rojnuckarin, Cheng Shyong Chang, Kian Meng Chang, Meng Yao Lu, Wen Li Hwang, Liang Piu Koh, Tsai Yun Chen, Anskar Yh Leung, Lalita Norasetthada, Shih Chung Wang, Ming Chih Chang, Kang Hsi Wu, Surapol Issaragrisil

研究成果: Article同行評審

12 引文 斯高帕斯(Scopus)

摘要

Due to the unavailability of horse antithymocyte globulin (ATG) in many markets worldwide, patients with severe aplastic anemia (SAA) are limited to the use of rabbit ATG. We aimed to analyze hematologic response and overall survival (OS) of Asian patients treated with rabbit ATG as first-line therapy of SAA. We retrospectively reviewed the medical records of 97 consecutive patients who received rabbit ATG as first-line treatment of SAA from 2006 to 2012 at centers in four Asian countries. The primary endpoint was 6- and 12-month overall response rates (ORR) for patients receiving rabbit ATG within the recommended dose range (2.5–3.75 mg/kg/day). Secondary endpoints included ORR in patients receiving any dose of rabbit ATG and 2-year OS. For patients who received rabbit ATG within the recommended dose range, 6- and 12-month ORRs were 17.4 and 63.6 %, respectively. For patients who received any dose of rabbit ATG, 6- and 12-month ORRs were 24.3 and 68.6 %, respectively. The 2-year OS rate was 86.3 %. Rabbit ATG is effective for treatment of SAA in Asian patients. The 12-month ORR and 2-year OS with rabbit ATG were comparable to historical results obtained with horse ATG.

原文English
頁(從 - 到)454-461
頁數8
期刊International Journal of Hematology
104
發行號4
DOIs
出版狀態Published - 2016 十月 1

All Science Journal Classification (ASJC) codes

  • Hematology

指紋 深入研究「Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study」主題。共同形成了獨特的指紋。

引用此